Cargando…

Surrogate end points and their role in clinical trial

Detalles Bibliográficos
Autor principal:	Jaykaran
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825018/ https://www.ncbi.nlm.nih.gov/pubmed/20177585 http://dx.doi.org/10.4103/0253-7613.48880

Ejemplares similares

Surrogate end points and their role in clinical trials: Reply from authors
por: Kalikar, M.V., et al.
Publicado: (2009)

Protein C as a surrogate end-point for clinical trials of sepsis
por: Liu, Kathleen D, et al.
Publicado: (2008)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Debate: Are surrogate end-point studies worth the effort?
por: Valabhji, Jonathan, et al.
Publicado: (2000)

The Mouse Uterotrophic Assay: Other End Points
por: Newbold, RR
Publicado: (2001)

Applying Desirability of Outcome Ranking End Points
por: Dunne, Michael W, et al.
Publicado: (2023)

Is cytochrome modulation the new frontier for decreasing the risk of cataract?
por: Jaykaran,
Publicado: (2009)

Data transformation
por: Jaykaran,
Publicado: (2011)

“Mean ± SEM” or “Mean (SD)”?
por: Jaykaran,
Publicado: (2010)

Optimizing the implementation of future treatment using surrogate end-points
por: Dowsett, Mitch
Publicado: (2008)

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
por: Maeda, Hideki, et al.
Publicado: (2023)

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections
por: Dunne, Michael W, et al.
Publicado: (2023)

NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
por: Schmitt, Walter, et al.
Publicado: (2021)

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
por: Lee, L., et al.
Publicado: (2011)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
por: Burzykowski, Tomasz, et al.
Publicado: (2019)

Imaging dopamine neurotransmission in Parkinson's disease: biomarker versus surrogate end point
por: Innis, Robert B.
Publicado: (2004)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Distance of residence in 1984 may be used as exposure surrogate for the Bhopal disaster
por: Dhara, V. Ramana, et al.
Publicado: (2012)

Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation
por: Staub, Lukas P, et al.
Publicado: (2012)

Who should be responsible for the care of advanced chronic kidney disease? Do the guidelines point to the end of nephrology follow-up of advanced CKD or are they the starting point for a new approach?
por: Piccoli, Giorgina Barbara
Publicado: (2020)

Comment on “Effects of in Utero Exposure to Arsenic during the Second Half of Gestation on Reproductive End Points and Metabolic Parameters in Female CD-1 Mice”
por: Williams, Amy L., et al.
Publicado: (2016)

Surrogate end points of quality of life assessment: have we really found what we are looking for?
por: Tassinari, Davide
Publicado: (2003)

Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point
por: ZHANG, BO, et al.
Publicado: (2016)

Regarding distance of residence in 1984 may be used as exposure surrogate for the Bhopal disaster - further observations on post-disaster epidemiology
por: Dhara, V. Ramana, et al.
Publicado: (2013)

Response to “Comment on ‘Effects of in Utero Exposure to Arsenic during the Second Half of Gestation on Reproductive End Points and Metabolic Parameters in Female CD-1 Mice’”
por: Rodriguez, Karina F., et al.
Publicado: (2016)

Surrogate markers in antiangiogenesis clinical trials
por: Davis, D W, et al.
Publicado: (2003)

Point-of-Care Ultrasound Findings and Clinical Outcomes in Patients with COVID-19
por: Iyengar-Kapuganti, Rupa L., et al.
Publicado: (2020)

Clinical Trial End Points in Severe COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Points from Letters
Publicado: (1947)

Points from Letters
Publicado: (1949)

End-of-2021 stocktake update
por: Weightman, Michael, et al.
Publicado: (2022)

End-of-2022 stocktake update
por: Weightman, Michael, et al.
Publicado: (2023)

Neurogenic Inflammation: Additional Points
por: Shusterman, Dennis
Publicado: (1994)

Some Points in Snake-Bite
por: Banerjee, K. C.
Publicado: (1926)

Points from a Letter
Publicado: (1950)

The Beginning of the End—The Knell of Sectarianism in Medicine
por: Rochester, DeLancey
Publicado: (1902)

Registering clinical trials
por: Lie, Frank
Publicado: (2004)

Cigarettes: Point Source for Benzene Exposure?
por: Wallace, Lance
Publicado: (1993)

Users’ guide to point‐of‐care ultrasonography
por: Tanael, Michael
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8oeubgq29viasmq26pnn8q78kh